Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 12Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Interventional × Raloxifene Hydrochloride × Clear all
NCT06055179 2025-07-01

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Guangzhou University of Traditional Chinese Medicine

Phase NA Recruiting
98 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡